New 2021 publication about the benefits of Trimetazidine and Bisoprolol to treat symptomatic patients with Chronic Coronary Syndrome

The 2019 ESC guidelines for the diagnostic and management of Chronic Coronary Syndrome (CCS) acknowledge that cardiac ischemia has different facets and that the treatment of patients with chronic coronary syndrome should be adapted to each patients' characteristics and preferences1.

Ischemic heart disease being the first cause of death worldwide2, an adequate management of patients is essential to curb the progression to more severe heart diseases, such as heart failure. Servier offers several solutions for these symptomatic patients with chronic coronary syndrome.

Despite the widespread use of Beta Blocker, a high proportion of patients with stable angina continue to experience ischemia and anginal pain. The early combination Vastarel + Beta-Blocker reduces the angina attacks and improves exercise capacity of angina patients

1. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes​

2. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death